188 related articles for article (PubMed ID: 35613022)
41. Azacitidine Use for Myeloid Neoplasms.
El Fakih R; Komrokji R; Shaheen M; Almohareb F; Rasheed W; Hassanein M
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):e147-e155. PubMed ID: 29478947
[TBL] [Abstract][Full Text] [Related]
42. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.
Chien KS; Class CA; Montalban-Bravo G; Wei Y; Sasaki K; Naqvi K; Ganan-Gomez I; Yang H; Soltysiak KA; Kanagal-Shamanna R; Do KA; Kantarjian HM; Garcia-Manero G
Leuk Lymphoma; 2020 Jun; 61(6):1493-1499. PubMed ID: 32036728
[TBL] [Abstract][Full Text] [Related]
43. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/β-catenin pathway in esophageal squamous cell carcinoma.
He J; Zhou M; Chen X; Yue D; Yang L; Qin G; Zhang Z; Gao Q; Wang D; Zhang C; Huang L; Wang L; Zhang B; Yu J; Zhang Y
J Exp Clin Cancer Res; 2016 Jun; 35(1):98. PubMed ID: 27329034
[TBL] [Abstract][Full Text] [Related]
45. [Changes of WT1 mRNA expression level in patients with myelodysplastic syndromes after hypomethylating agents and its prognostic significance].
Zhang HY; Geng SX; Li MM; Lai PL; Deng CX; Lu ZS; Huang X; Wang YL; Weng JY; Du X
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):417-421. PubMed ID: 31207708
[No Abstract] [Full Text] [Related]
46. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
[TBL] [Abstract][Full Text] [Related]
47. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
[TBL] [Abstract][Full Text] [Related]
48. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
Ball B; Zeidan A; Gore SD; Prebet T
Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
[TBL] [Abstract][Full Text] [Related]
49. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Jabbour E; Faderl S; Sasaki K; Kadia T; Daver N; Pemmaraju N; Patel K; Khoury JD; Bueso-Ramos C; Bohannan Z; Ravandi F; Borthakur G; Verstovsek S; Miller D; Maduike R; Hosing C; Kantarjian HM; Garcia-Manero G
Cancer; 2017 Feb; 123(4):629-637. PubMed ID: 27741352
[TBL] [Abstract][Full Text] [Related]
50. SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.
Sun B; Xu L; Bi W; Ou WB
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216168
[TBL] [Abstract][Full Text] [Related]
51. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP; Zeidan AM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
[TBL] [Abstract][Full Text] [Related]
52. SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes.
Jeong HW; Cui W; Yang Y; Lu J; He J; Li A; Song D; Guo Y; Liu BH; Chai L
PLoS One; 2011 Apr; 6(4):e18372. PubMed ID: 21526180
[TBL] [Abstract][Full Text] [Related]
53. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.
Jung SH; Kim YJ; Yim SH; Kim HJ; Kwon YR; Hur EH; Goo BK; Choi YS; Lee SH; Chung YJ; Lee JH
Oncotarget; 2016 Aug; 7(34):55264-55275. PubMed ID: 27419369
[TBL] [Abstract][Full Text] [Related]
54. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
[TBL] [Abstract][Full Text] [Related]
55. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
Silverman LR
Leuk Res; 2009 Dec; 33 Suppl 2():S18-21. PubMed ID: 20004792
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of Sal-like protein 4 in head and neck cancer: epigenetic effects and clinical correlations.
Misawa K; Misawa Y; Mima M; Yamada S; Imai A; Mochizuki D; Nakagawa T; Kurokawa T; Endo S; Kawasaki H; Brenner JC; Mineta H
Cell Oncol (Dordr); 2020 Aug; 43(4):631-641. PubMed ID: 32240499
[TBL] [Abstract][Full Text] [Related]
57. Dissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome.
Tatetsu H; Watanabe M; Liu J; Tokunaga K; Iwanaga E; Komohara Y; Thrash E; Bassal MA; Matsuoka M; Tenen DG; Chai L
Clin Transl Med; 2023 Aug; 13(8):e1327. PubMed ID: 37501279
[No Abstract] [Full Text] [Related]
58. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
[TBL] [Abstract][Full Text] [Related]
59. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
60. Use of hypomethylating agents in myelodysplastic syndromes.
Atallah E; Garcia-Manero G
Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
